BMI1 and neoplasm: Recently, it has been demonstrated that combination therapy with PTC-209 augmented PD1 immune checkpoint blockade and eliminated BMI1+ CSCs by inducing tumor cell-intrinsic immunity, resulting in the inhibition of metastasis and relapse of HNSCC in vivo [192].